Full Coverage
F.D.A. Approves Alzheimer's Drug Despite Fierce Debate Over Whether It Works (Published 2021)
By Pam Belluck & Rebecca Robbins
Top news
NIA statement on FDA approval of aducanumab for Alzheimer's disease
Biogen CEO says $56,000 annually for Alzheimer’s drug is 'fair,' promises not to hike price for at least 4 years
By Berkeley Lovelace & Berkeley Lovelace Jr.
Biogen's shockingly broad Aduhelm label—and $56K price—set up a $10B launch, analysts say
By Noah Higgins-Dunn
An extra twist in the FDA's Alzheimer's decision: no limits on which patients can get the drug
By Andrew Joseph
All coverage
U.S. approval of Biogen Alzheimer's drug sends shares soaring, hailed as 'big day" for patients
By Julie Steenhuysen & Deena Beasley
Controversial FDA Approval Of Alzheimer's Drug Aducanumab Sets Stage For Possible Medicare Coverage Battle
By Joshua Cohen
FDA approves first drug intended to slow cognitive decline caused by Alzheimer's disease
By Laurie McGinley
In controversial decision, FDA approves first new Alzheimer's disease drug in nearly 20 years
By Jacqueline Howard
Alzheimer's drug from Biogen wins US approval
By Nikou Asgari
New Alzheimer’s drug is 1st of its kind to be FDA approved
By Sony Salzman & Deepak Ramanathan
Alzheimer's Drug Poses a Dilemma for the F.D.A. (Published 2021)
By Pam Belluck & Rebecca Robbins
FDA Approves First New Alzheimer's Drug in Nearly Two Decades
By Joseph Walker
Biogen faces tough questions over $56K-a-year price of newly approved Alzheimer's drug
By Berkeley Lovelace & Berkeley Lovelace Jr.
Biogen shares surge 38% after FDA approves Alzheimer's drug, the first new therapy for the disease in nearly two decades
By Berkeley Lovelace & Berkeley Lovelace Jr.
Aducanumab: FDA Approves Controversial Alzheimer's Drug
By Jon Hamilton, Scott Hensley & Laurel Wamsley
Why Biogen may be sitting on the most lucrative product in pharmaceutical history
By Adam Feuerstein & Damian Garde
Alzheimer's Drug Is Bonanza for Biogen, Most Likely at Taxpayer Expense (Published 2021)
By Pam Belluck & Rebecca Robbins